- Home
- SSSS vs ENTA Comparison
SSSS vs ENTA Comparison
Compare SSSS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- ENTA
- Stock Information
- Founded
- SSSS 2010
- ENTA 1995
- Country
- SSSS United States
- ENTA United States
- Employees
- SSSS N/A
- ENTA N/A
- Industry
- SSSS Finance: Consumer Services
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- ENTA Health Care
- Exchange
- SSSS Nasdaq
- ENTA Nasdaq
- Market Cap
- SSSS 138.2M
- ENTA 164.6M
- IPO Year
- SSSS N/A
- ENTA 2013
- Fundamental
- Price
- SSSS $8.27
- ENTA $7.11
- Analyst Decision
- SSSS Strong Buy
- ENTA Buy
- Analyst Count
- SSSS 4
- ENTA 5
- Target Price
- SSSS $9.50
- ENTA $18.40
- AVG Volume (30 Days)
- SSSS 202.2K
- ENTA 181.2K
- Earning Date
- SSSS 08-11-2025
- ENTA 08-08-2025
- Dividend Yield
- SSSS 12.09%
- ENTA N/A
- EPS Growth
- SSSS N/A
- ENTA N/A
- EPS
- SSSS N/A
- ENTA N/A
- Revenue
- SSSS $3,644,430.00
- ENTA $64,462,999.00
- Revenue This Year
- SSSS $6.95
- ENTA N/A
- Revenue Next Year
- SSSS N/A
- ENTA $2.75
- P/E Ratio
- SSSS N/A
- ENTA N/A
- Revenue Growth
- SSSS N/A
- ENTA N/A
- 52 Week Low
- SSSS $3.52
- ENTA $4.09
- 52 Week High
- SSSS $9.12
- ENTA $15.11
- Technical
- Relative Strength Index (RSI)
- SSSS 50.46
- ENTA 45.78
- Support Level
- SSSS $8.18
- ENTA $7.15
- Resistance Level
- SSSS $8.70
- ENTA $8.31
- Average True Range (ATR)
- SSSS 0.32
- ENTA 0.50
- MACD
- SSSS -0.10
- ENTA -0.03
- Stochastic Oscillator
- SSSS 14.14
- ENTA 36.00
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.